Abstract:Objectives Approximately one in eight practices in primary care in England are ‘dispensing practices’ with an in-house dispensary providing medication directly to patients. These practices can generate additional income by negotiating lower prices on higher cost drugs, while being reimbursed at a standard rate. They, therefore, have a potential financial conflict of interest around prescribing choices. We aimed to determine whether dispensing practices are more likely to prescribe high-cost options for four commonly prescribed classes of drug where there is no evidence of superiority for high-cost options. Design A list was generated of drugs with high acquisition costs that were no more clinically effective than those with the lowest acquisition costs, for all four classes of drug examined. Data were obtained prescribing of statins, proton pump inhibitors (PPIs), angiotensin receptor blockers (ARBs) and ACE inhibitors (ACEis). Logistic regression was used to calculate ORs for prescribing high-cost options in dispensing practices, adjusting for Index of Multiple Deprivation score, practice list size and the number of doctors at each practice. Setting English primary care. Participants All general practices in England. Main outcome measures Mean cost per dose was calculated separately for dispensing and non-dispensing practices. Dispensing practices can vary in the number of patients they dispense to; we, therefore, additionally compared practices with no dispensing patients, low, medium and high proportions of dispensing patients. Total cost savings were modelled by applying the mean cost per dose from non-dispensing practices to the number of doses prescribed in dispensing practices. Results Dispensing practices were more likely to prescribe high-cost drugs across all classes: statins adjusted OR 1.51 (95% CI 1.49 to 1.53, p<0.0001), PPIs OR 1.11 (95% CI 1.09 to 1.13, p<0.0001), ACEi OR 2.58 (95% CI 2.46 to 2.70, p<0.0001), ARB OR 5.11 (95% CI 5.02 to 5.20, p<0.0001). Mean cost per dose in pence was higher in dispensing practices (statins 7.44 vs 6.27, PPIs 5.57 vs 5.46, ACEi 4.30 vs 4.24, ARB 11.09 vs 8.19). For all drug classes, the more dispensing patients a practice had, the more likely it was to issue a prescription for a high-cost option. Total cost savings in England available from all four classes are £628 875 per month or £7 546 502 per year. Conclusions Doctors in dispensing practices are more likely to prescribe higher cost drugs. This is the largest study ever conducted on dispensing practices, and the first contemporary research suggesting some UK doctors respond to a financial conflict of interest in treatment decisions. The reimbursement system for dispensing practices may generate unintended consequences. Robust routine audit of practices prescribing higher volumes of unnecessarily expensive drugs may help reduce costs.

Cost Of Hospital Prescribing Rose 15% In A Year Owing To New Rheumatoid Arthritis And Cancer Drugs

The rising cost of rhinologic medications

National trends in prescription drug expenditures and projections for 2024

Hospital Prescribing of Antibiotics Rose Significantly Between 2011 and 2014

NHS Hospital Drug Costs Are Set to Surpass Spending in Primary Care

Cancer Drugs Fund Receives Boost but Will No Longer Fund “overpriced” Drugs

Antineoplastic Prescription among Patients with Colorectal Cancer in Eight Major Cities of China, 2015–2019: an Observational Retrospective Database Analysis

The increasing costs of medicines and their implications for patients, physicians and the health system

Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007-20

Association between changes in prices and out‐of‐pocket costs for brand‐name clinician‐administered drugs

Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data

Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling study

Spending on and Use of Clinician-Administered Drugs in Medicare

Nice Sets Cap On Drugs Costing More Than 20m Pound

Hospital Prices for Physician-Administered Drugs

Nhs England Drops 16 Medicines From Cancer Drugs Fund

The economic pressures for biosimilar drug use in cancer medicine

Hospitalization Expense of Patients with Rheumatoid Arthritis from Urban Area in China and Its Influential Factors

Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?

Evaluation of Specialty Drug Price Trends Using Data from Retrospective Pharmacy Sales Transactions

A multicenter study of costs of drugs in rheumatoid arthritis in China